Actuate Therapeutics IncACTUNASDAQ
Loading
Operating Expenses Over TimeStable
Percentile Rank33
3Y CAGR+6.4%
Studio
Year-over-Year Change

Expenses from normal business operations (SG&A, R&D, etc.)

3Y CAGR
+6.4%/yr
Annual compound
Percentile
P33
Within normal range
vs 3Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineStable
PeriodValueYoY Change
TTM$24.37M-3.2%
2024$25.16M+0.7%
2023$24.97M+23.6%
2022$20.21M-